Literature DB >> 6361060

Enzyme-linked immunosorbent assay compared with neutralization tests for evaluation of live mumps vaccines.

H Sakata, M Hishiyama, A Sugiura.   

Abstract

Mumps-specific antibody levels before and after vaccination with live mumps vaccines were determined by enzyme-linked immunosorbent assay (ELISA) and neutralization tests. A correlation was found between neutralization titers and optical density in ELISA. However, postvaccination sera from some vaccinees who failed to seroconvert by neutralization contained significant levels of mumps-specific antibody detectable by ELISA. In some of these serum specimens, the antibody directed to the F polypeptide of mumps virus was predominant. Most sera positive in ELISA neutralized mumps virus upon the addition of fresh guinea pig serum to the virus-serum mixture.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6361060      PMCID： PMC270970          DOI： 10.1128/jcm.19.1.21-25.1984

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  22 in total

1.  Structural polypeptides of mumps virus.

Authors:  C Orvell
Journal:  J Gen Virol       Date:  1978-12       Impact factor: 3.891

2.  Evaluation of enzyme-linked immunosorbent assay (ELISA) for mumps virus antibodies.

Authors:  P O Leinikki; I Shekarchi; N Tzan; D L Madden; J L Sever
Journal:  Proc Soc Exp Biol Med       Date:  1979-03

3.  Studies on live mumps virus vaccine. V. Development of a new mumps vaccine "AM 9" by plaque cloning.

Authors:  K Yamanishi; M Takahashi; S Ueda; Y Minekawa; T Ogino
Journal:  Biken J       Date:  1973-12

4.  A film detection method for tritium-labelled proteins and nucleic acids in polyacrylamide gels.

Authors:  W M Bonner; R A Laskey
Journal:  Eur J Biochem       Date:  1974-07-01

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Immunological properties of purified mumps virus glycoproteins.

Authors:  C Orvell
Journal:  J Gen Virol       Date:  1978-12       Impact factor: 3.891

7.  The polypeptides of mumps virus and their synthesis in infected chick embryo cells.

Authors:  H Naruse; Y Nagai; T Yoshida; M Hamaguchi; T Matsumoto; S Isomura; S Suzuki
Journal:  Virology       Date:  1981-07-15       Impact factor: 3.616

8.  Evidence for a ninth influenza viral polypeptide.

Authors:  R A Lamb; P R Etkind; P W Choppin
Journal:  Virology       Date:  1978-11       Impact factor: 3.616

9.  Live attenuated mumps-virus vaccine. IV. Protective efficacy as measured in a field evaluation.

Authors:  M R Hilleman; R E Weibel; E B Buynak; J Stokes; J E Whitman
Journal:  N Engl J Med       Date:  1967-02-02       Impact factor: 91.245

10.  Identification of paramyxovirus-specific haemolysis-inhibiting antibodies separate from haemagglutinating-inhibiting and neuraminidase-inhibiting antibodies. 2. NDV and mumps virus haemolysis-inhibiting antibodies.

Authors:  C Orvell
Journal:  Acta Pathol Microbiol Scand B       Date:  1976-12
View more
  13 in total

1.  Comparison of a neutralization enzyme immunoassay and an enzyme-linked immunosorbent assay for evaluation of immune status of children vaccinated for mumps.

Authors:  T Harmsen; M C Jongerius; C W van der Zwan; A D Plantinga; C A Kraaijeveld; G A Berbers
Journal:  J Clin Microbiol       Date:  1992-08       Impact factor: 5.948

2.  Evaluation of two enzyme immunoassays for detection of immunoglobulin G antibodies to mumps virus.

Authors:  J L Backhouse; H F Gidding; P B McIntyre; G L Gilbert
Journal:  Clin Vaccine Immunol       Date:  2006-07

3.  Standardization of measles, mumps and rubella assays to enable comparisons of seroprevalence data across 21 European countries and Australia.

Authors:  A Tischer; N Andrews; G Kafatos; A Nardone; G Berbers; I Davidkin; Y Aboudy; J Backhouse; C Barbara; K Bartha; B Bruckova; A Duks; A Griskevicius; L Hesketh; K Johansen; L Jones; O Kuersteiner; E Lupulescu; Z Mihneva; M Mrazova; F De Ory; K Prosenc; F Schneider; A Tsakris; M Smelhausova; R Vranckx; M Zarvou; E Miller
Journal:  Epidemiol Infect       Date:  2007-03-30       Impact factor: 2.451

4.  Monoclonal antibodies directed to E1 glycoprotein of rubella virus.

Authors:  Y Umino; T A Sato; S Katow; T Matsuno; A Sugiura
Journal:  Arch Virol       Date:  1985       Impact factor: 2.574

5.  Non-invasive method for early diagnosis of herpes simplex encephalitis.

Authors:  N Hanada; S Kido; M Terashima; K Nishikawa; T Morishima
Journal:  Arch Dis Child       Date:  1988-12       Impact factor: 3.791

6.  The risk of measles, mumps, and varicella among young adults: a serosurvey of US Navy and Marine Corps recruits.

Authors:  J P Struewing; K C Hyams; J E Tueller; G C Gray
Journal:  Am J Public Health       Date:  1993-12       Impact factor: 9.308

7.  Immunological studies on adult T cell leukaemia virus (ATLV) carriers.

Authors:  Y Morishima; K Ohya; T Morishima; K Nishikawa; T Fukuda
Journal:  Clin Exp Immunol       Date:  1986-06       Impact factor: 4.330

8.  Viruses within the Flaviviridae decrease CD4 expression and inhibit HIV replication in human CD4+ cells.

Authors:  Jinhua Xiang; James H McLinden; Robert A Rydze; Qing Chang; Thomas M Kaufman; Donna Klinzman; Jack T Stapleton
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

9.  Replication of mumps virus in mouse: transient replication in lung and potential of systemic infection.

Authors:  M Tsurudome; A Yamada; M Hishiyama; Y Ito
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

10.  Functional and structural characterization of neutralizing epitopes of measles virus hemagglutinin protein.

Authors:  Maino Tahara; Yuri Ito; Melinda A Brindley; Xuemin Ma; Jilan He; Songtao Xu; Hideo Fukuhara; Kouji Sakai; Katsuhiro Komase; Paul A Rota; Richard K Plemper; Katsumi Maenaka; Makoto Takeda
Journal:  J Virol       Date:  2012-10-31       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.